Drugs / Ad5CMV-p53 gene
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT00004041 | Feb 1999 → Jul 2002 | central nervous system neoplasm | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Completed | No outcome recorded |
| Phase 1 | NCT00003167 | May 1998 → Dec 2002 | bladder transitional cell carcinoma | National Cancer Institute (NCI) | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Ad5CMV-p53 gene | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00004041 ↗ |
| Known as | Ad-p53 | “adenovirus p53 gene (Ad-p53)” NCT00004041 ↗ |
| Route | Other | “Given intravesically” NCT00003167 ↗ |
| Target | TP53 | “Inserting the p53 gene into a person's bladder cancer cells” NCT00003167 ↗ |